CIK 0001503802
- Non-accelerated filer
- Smaller reporting company
Karyopharm Therapeutics Inc.
Sign in to watch- Tickers
- KPTI KPTIQ
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 263931704
- Phone
- +1 617-658-0600
- Business address
- 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 02459
Securities
- KPTI Common stock Nasdaq
- KPTIQ Common stock
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,135
- in 3 filings
Net −$2,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-28 | Mason Michael EVP, CFO & Treasurer | Sale | −2,398 | $10.24 | $25K | 139,110 |
| 2022-02-28 | Mason Michael EVP, CFO & Treasurer | Grant or award · Stock Option (right to buy) | +111,600 | 111,600 | ||
| 2022-02-28 | Shacham Sharon Chief Scientific Officer | Sale | −6,226 | $10.24 | $64K | 898,131 |
| 2022-02-28 | Shacham Sharon Chief Scientific Officer | Grant or award | +21,000 | 719,983 | ||
| 2022-02-28 | Shacham Sharon Chief Scientific Officer | Sale | −6,226 | $10.24 | $64K | 713,757 |
| 2022-02-28 | Shacham Sharon Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2022-02-28 | Kauffman Michael Director | Grant or award | +21,000 | 719,983 | ||
| 2022-02-28 | Kauffman Michael Director | Sale | −6,226 | $10.24 | $64K | 713,757 |
| 2022-02-28 | Kauffman Michael Director | Sale | −6,226 | $10.24 | $64K | 898,131 |
| 2022-02-28 | Kauffman Michael Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2022-02-28 | Mitchener Stephen SVP, Chief Business Officer | Grant or award | +47,250 | 50,546 | ||
| 2022-02-28 | Mitchener Stephen SVP, Chief Business Officer | Grant or award · Stock Option (right to buy) | +59,400 | 59,400 | ||
| 2022-02-28 | Cheng Sohanya Roshan Chief Commercial Officer | Grant or award | +84,000 | 91,500 | ||
| 2022-02-28 | Cheng Sohanya Roshan Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +108,000 | 108,000 | ||
| 2022-02-28 | Mano Michael SVP, General Counsel&Secretary | Grant or award | +63,000 | 63,000 | ||
| 2022-02-28 | Mano Michael SVP, General Counsel&Secretary | Grant or award · Stock Option (right to buy) | +81,000 | 81,000 | ||
| 2022-02-28 | Paulson Richard A. President and CEO | Grant or award | +288,750 | 661,950 | ||
| 2022-02-28 | Paulson Richard A. President and CEO | Grant or award · Stock Option (right to buy) | +360,000 | 360,000 | ||
| 2022-02-17 | Shah Jatin EVP, Chief Medical Officer | Sale | −1,306 | $12.12 | $16K | 129,450 |
| 2022-02-17 | Frenkel Ran EVP, Chief Dev. Officer | Sale | −2,929 | $12.12 | $36K | 101,703 |
Page 14 of 15 · 287 trades